Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic

Authors

  • Richard Hall WHO National Influenza Centre, Institute of Environmental Science & Research, National Centre for Biosecurity & Infectious Disease, New Zealand.
  • Matthew Peacey
  • Jacqui Ralston
  • Danielle de Joux
  • Judy Bocacao
  • Mackenzie Nicol
  • Molly Ziki
  • Wendy Gunn
  • Jing Wang
  • Q Sue Huang

DOI:

https://doi.org/10.5365/wpsar.2012.3.3.002

Abstract

Introduction: Oseltamivir (Tamiflu®) is an important pharmaceutical intervention against the influenza virus. The importance of surveillance for resistance to oseltamivir has been highlighted by two global events: the emergence of an oseltamivir-resistant seasonal influenza A(H1N1) virus in 2008, and emergence of the influenza A(H1N1)pdm09 virus in 2009. Oseltamivir is a prescription medicine in New Zealand, but more timely access has been provided since 2007 by allowing pharmacies to directly dispense oseltamivir to patients with influenza-like illness.

Objective: To determine the frequency of oseltamivir-resistance in the context of a medicine reclassification in 2007, the importation of an oseltamivir-resistant seasonal influenza virus in 2008, and the emergence of a pandemic in 2009.

Methods: A total of 1795 influenza viruses were tested for oseltamivir-resistance using a fluorometric neuraminidase inhibition assay. Viruses were collected as part of a sentinel influenza surveillance programme between the years 2006 and 2010.

Results: All influenza B, influenza A(H3N2) and influenza A(H1N1)pdm09 viruses tested between 2006 and 2010 were shown to be sensitive to oseltamivir. Seasonal influenza A(H1N1) viruses from 2008 and 2009 were resistant to oseltamivir. Sequencing of the neuraminidase gene showed that the resistant viruses contained an H275Y mutation, and S247N was also identified in the neuraminidase gene of one seasonal influenza A(H1N1) virus that exhibited enhanced resistance.

Discussion: No evidence was found to suggest that increased access to oseltamivir has promoted resistance. A probable importation event was documented for the global 2008 oseltamivir-resistant seasonal A(H1N1) virus nine months after it was first reported in Europe in January 2008.

Downloads

How to Cite

1.
Hall R, Peacey M, Ralston J, de Joux D, Bocacao J, Nicol M, Ziki M, Gunn W, Wang J, Huang QS. Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic. Western Pac Surveill Response J [Internet]. 2013 May 30 [cited 2026 Mar. 25];3(4). Available from: https://ojs.wpro.who.int/ojs/index.php/wpsar/article/view/181

Issue

Vol. 3 No. 4 (2012): October – December

Section

Other topic - Original Research

License

You are free to:

  • Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

When the Licensor is an intergovernmental organization, disputes will be resolved by mediation and arbitration unless otherwise agreed.

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

Most read articles by the same author(s)